(최근 5개년)

• Reoperation versus dose-escalated radiotherapy for ductal carcinoma in situ at the surgical margin after breast-conserving surgery for invasive ductal carcinoma. J Breast Cancer. 2025;28(6):381-392 (2.4)
• Comprehensive review of Peutz–Jeghers syndrome: genetics, clinical manifestations, and management strategies. Lab Med Online. 2025;15(4):277-285
• Impact of a 24-week mobile app-based human coaching program on body composition and lipid metabolism in breast cancer survivors with overweight or obesity: single-arm prospective cohort study. JMIR Mhealth Uhealth. 2025;13:e64846 (6.2)
• Effectiveness of multi-layer perceptron-based binary classification neural network in detecting breast cancer through nine human serum protein markers. Cancers (Basel). 2025;17(17):2832 (4.4)
• ASO author reflections: multimodal sentinel lymph node mapping in breast cancer: efficacy and clinical implications after neoadjuvant chemotherapy. Ann Surg Oncol. 2025;32:8806-8807 (3.5)
• Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors. Breast Cancer Res Treat. 2025;213(3):325-334 (3)
• Clinical application of multimodal sentinel lymph node-mapping method for patients with breast cancer undergoing neoadjuvant chemotherapy: a final analysis. Ann Surg Oncol. 2025;32:8728-8734 (3.5)
• Additional prognostic value of the BCT score in ER+HER2- breast cancer patients receiving a 21-gene assay-guided adjuvant treatments. Front Oncol. 2025;15:1517073 (3.3)
• Outcomes and effectiveness of decision aids for families affected by hereditary cancer syndromes: a scoping review. Genet Med. 2025;27(7):101424 (6.2)
• Mortality prediction modeling for patients with breast cancer based on explainable machine learning. Cancers (Basel). 2024;16(22):3799 (4.5)
• Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA substudy. Breast Cancer Res. 2024;26:152 (6.1)
• Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance. Exp Mol Med. 2024;56:2382-2394 (9.5)
• Unveiling the clinical path of microinvasive breast cancer: a comparative study with Tis–T1 breast cancer. Cancer Med. 2024;13(19):e70297 (2.9)
• Case report: extraskeletal Ewing sarcoma with a germline pathogenic variant of SMARCA4. Front Oncol. 2024;14:1422605 (3.5)
• Neoadjuvant chemotherapy with concurrent letrozole for estrogen receptor-positive and HER2-negative breast cancer: an open-label, single-center, nonrandomized phase II study (NeoCHAI). Cancers (Basel). 2024;16(18):3122 (4.5)
• Surveillance for distant metastasis in breast cancer patients who underwent contemporary management: a report from the Korean Breast Cancer Society survivor research group. Ann Surg Oncol. 2024;31:6774-6785 (3.4)
• ASO author reflections: assessing the efficacy of multimodal sentinel lymph node mapping in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2024;31(10):6841-6842 (3.4)
• Comparison of concordance of tumor size measured using ultrasonography, magnetic resonance imaging, and pathology in breast cancer. J Surg Ultrasound. 2024;11:25-31 (0.12)
• Healthcare professionals’ learning needs and perspectives on essential information in genetic cancer care: a systematic review. Cancers (Basel). 2024;16(11):1963 (4.5)
• Clinical application of multimodal sentinel lymph node mapping method in patients with breast cancer undergoing neoadjuvant chemotherapy: an interim analysis. Ann Surg Oncol. 2024;31:5141-5147 (3.4)
• Case report of desmoid fibromatosis as a rare disease entity of the breast. J Breast Dis. 2023
• Health-related quality of life in long-term early-stage breast cancer survivors compared to general population in Korea. J Cancer Surviv. 2023 (3.7)
• Questionnaire study of application about sentinel lymph node biopsy surgery in locally advanced breast cancer patients who received neoadjuvant chemotherapy. Front Oncol. 2023;13:1235938 (4.7)
• Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study. Front Oncol. 2023;13:1208320 (4.7)
• Clinicopathological factors associated with Oncotype DX risk group in patients with ER+/HER2- breast cancer. Cancers (Basel). 2023;15(18):4451 (5.2)
• Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J Clin Oncol. 2023;41(31):4864-4871 (45.4)
• Clinical features of Li-Fraumeni syndrome in Korea. Cancer Res Treat. 2023;56(1):334-341 (4.6)
• Progranulin and breast cancer mortality: 13-year follow-up of a cohort study. Breast Cancer (Targets Ther). 2023;15:251-261 (2.6)
• Health-seeking behavior returning to normalcy overcoming COVID-19 threat in breast cancer. Cancer Res Treat. 2023;55(4):1222-1230 (4.6)
• Androgen receptor as a predictive marker for pathologic complete response in hormone receptor-positive and HER2-negative breast cancer with neoadjuvant chemotherapy. Cancer Res Treat. 2022 (5.036)
• Long-term trajectory of postoperative health-related quality of life in young breast cancer patients: a 15-year follow-up study. J Cancer Surviv. 2022 (4.062)
• Fear of cancer recurrence and its negative impact on health-related quality of life in long-term breast cancer survivors. Cancer Res Treat. 2021 (4.679)
• Sentinel lymph node biopsy in breast cancer patients with pathological complete response in the axillary lymph node after neoadjuvant chemotherapy. J Breast Cancer. 2021;24(6):531-541 (3.588)
• Clinical effectiveness of hypofractionated proton beam therapy for liver metastasis from breast cancer. Front Oncol. 2021;11:783327 (6.244)
• Surgical outcomes of localization using indocyanine green fluorescence in breast conserving surgery: a prospective study. Sci Rep. 2021;11(1):9997 (4.38)
• Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry. Breast Cancer Res Treat. 2021;187(3):785-792 (4.872)